In 2016, AxxessBio and EUSA Pharma entered into an exclusive agreement to supply Caphosol Solution and Caphosol Dispersible tablets in selected countries of Southeast Asia.
Caphosol is a mouthwash indicated for the prevention and treatment of oral mucositis due to cancer chemotherapy or radiation. It is a supersaturated solution of calcium and phosphate that coats the lining of the mouth, the tongue and oropharynx maintaining the integrity of the oral cavity. It can also be used to treat severe mouth dryness.
Oral mucositis is a debilitating complication of cancer therapy impacting the well- being of the patient and the outcome of treatment. It is often associated with pain, inability to drink or eat, and could be the portal for infection.
EUSA Pharma is a UK based global pharmaceutical company. It is committed to providing solutions in oncology and rare diseases continuously striving to confront gaps in patient care. For more information on the company and its products please visit http://eusapharma.com
